Ascendis Pharma A/S v. Biomarin Pharmaceutical Inc.
Headline: Appeals Court Affirms Non-Infringement Ruling in Patent Dispute Over Dwarfism Drug
Case Summary
This case involves a patent dispute between Ascendis Pharma A/S and Biomarin Pharmaceutical Inc. regarding a drug used to treat achondroplasia, a form of dwarfism. Ascendis sued Biomarin, alleging that Biomarin's drug, vosoritide, infringed on Ascendis's patent. The core of the dispute revolved around whether Biomarin's drug, which uses a C-terminal truncation, fell within the scope of Ascendis's patent claims, which describe a specific type of prodrug technology. The district court initially ruled in favor of Biomarin, finding that Biomarin's drug did not infringe Ascendis's patent because the C-terminal truncation was not equivalent to the 'linker' element described in Ascendis's patent claims. The district court also found that Ascendis's patent claims were invalid due to obviousness. Ascendis appealed this decision. The Court of Appeals for the Federal Circuit (CAFC) reviewed the district court's claim construction and its findings on infringement and obviousness. The CAFC affirmed the district court's judgment that Biomarin did not infringe Ascendis's patent. The CAFC agreed with the district court's interpretation of the patent claims, specifically the 'linker' element, and concluded that Biomarin's C-terminal truncation did not meet this definition, either literally or under the doctrine of equivalents. Because the CAFC affirmed the non-infringement finding, it did not need to reach the question of the patent's validity (obviousness). Therefore, Biomarin prevailed, and Ascendis's infringement claims were rejected.
AI-generated summary for informational purposes only. Not legal advice. May contain errors. Consult a licensed attorney for legal advice.
Key Holdings
The court established the following key holdings in this case:
- The C-terminal truncation used in Biomarin's drug vosoritide does not literally infringe Ascendis's patent claims, specifically the 'linker' element, as it does not meet the structural definition of a linker as a 'bifunctional moiety' connecting two components.
- Biomarin's C-terminal truncation does not infringe Ascendis's patent claims under the doctrine of equivalents because it does not perform substantially the same function in substantially the same way to achieve substantially the same result as the 'linker' element described in Ascendis's patent.
- When a district court's non-infringement finding is affirmed, an appellate court may decline to review the district court's alternative finding of patent invalidity.
Entities and Participants
Parties
- Ascendis Pharma A/S (party)
- Biomarin Pharmaceutical Inc. (party)
- cafc (party)
Frequently Asked Questions (5)
Comprehensive Q&A covering every aspect of this court opinion.
Basic Questions (5)
Q: What was this case about?
This case was a patent infringement lawsuit where Ascendis Pharma A/S accused Biomarin Pharmaceutical Inc. of infringing its patent related to a drug for treating achondroplasia, a form of dwarfism.
Q: What was the key technology at issue?
The key technology involved a prodrug design, specifically whether Biomarin's C-terminal truncation in its drug vosoritide infringed Ascendis's patent claims, which described a 'linker' element.
Q: How did the district court rule?
The district court ruled in favor of Biomarin, finding no infringement and also that Ascendis's patent claims were invalid due to obviousness.
Q: What was the outcome of the appeal?
The Court of Appeals for the Federal Circuit affirmed the district court's finding of non-infringement, meaning Biomarin won the appeal. The CAFC did not address the obviousness finding.
Q: Why did the appeals court affirm the non-infringement ruling?
The appeals court agreed with the district court's interpretation of the 'linker' element in Ascendis's patent and concluded that Biomarin's C-terminal truncation did not meet the definition of a linker, either literally or under the doctrine of equivalents.
Case Details
| Case Name | Ascendis Pharma A/S v. Biomarin Pharmaceutical Inc. |
| Court | cafc |
| Date Filed | 2026-03-26 |
| Docket Number | 26-1026 |
| Outcome | Defendant Win |
| Impact Score | 65 / 100 |
| Legal Topics | patent-infringement, claim-construction, doctrine-of-equivalents, obviousness, pharmaceutical-patents |
| Jurisdiction | federal |
About This Analysis
This AI-generated analysis of Ascendis Pharma A/S v. Biomarin Pharmaceutical Inc. was produced by CaseLawBrief to help legal professionals, researchers, students, and the general public understand this court opinion in plain English.
CaseLawBrief aggregates court opinions from CourtListener, a project of the Free Law Project, and enriches them with AI-powered analysis. Our goal is to make the law more accessible and understandable to everyone, regardless of their legal background.
AI-generated summary for informational purposes only. Not legal advice. May contain errors. Consult a licensed attorney for legal advice.